Latest Breaking News On - Steve pakola - Page 7 : comparemela.com

Wedbush Reiterates Neutral Rating for REGENXBIO (NASDAQ:RGNX)

REGENXBIO (NASDAQ:RGNX – Get Free Report)‘s stock had its “neutral” rating reissued by analysts at Wedbush in a research report issued on Wednesday, RTT News reports. They presently have a $21.00 target price on the biotechnology company’s stock. Wedbush’s price objective indicates a potential upside of 47.27% from the company’s previous close. Several other research […]

Stifel nicolausWilliam blairSteve pakolaCommonwealth of pennsylvania public school empls retrmtSecurities exchange commissionCompany profileMitsubishi ufjSigma planning corpYork mellon corpKokusai asset management coRoyal bankJennison associatesTechnology platformGet free reportExchange commissionPlanning corp

REGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery

A single ABBV-RGX-314 gene therapy treatment has the potential to become a new standard-of-care option among anti-VEGF treatments by sustaining vision health.

United statesNew mexicoChris brinzeySteve pakolaDana cormackRetina researchWills eye retina serviceEye associates of new mexicoExchange commissionTechnology platform licenseesSecurities exchangeClearside biomedical incCorporate communicationsTechnology platformHawaiian eyeJohn pitcher

Regenxbio (RGNX) Announces Positive Interim Data from Phase II AAVIATE Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery

Regenxbio (RGNX) Announces Positive Interim Data from Phase II AAVIATE Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New mexicoUnited statesSteve pakolaRetina researchRegenxbio incWills eye retina serviceEye associates of new mexicoHawaiian eyeEye associatesChief medical officer

REGENXBIO Inc (NASDAQ:RGNX) Q3 2023 Earnings Call Transcript

Operator: Good day, and thank you for standing by. Welcome to REGENXBIO s Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.

United statesSteve pakolaPatrick christmasRaymond jamesGena wangDane leoneWorld muscle societyExchange commissionRegenxbio incCall transcript novemberChief legalKen millsChief medical officerVit vasistaChief financial officerHawaiian eye

REGENXBIO Inc (NASDAQ:RGNX) Q3 2023 Earnings Call Transcript

REGENXBIO Inc. (NASDAQ:RGNX) Q3 2023 Earnings Call Transcript November 8, 2023 REGENXBIO Inc. beats earnings expectations. Reported EPS is $-1.41, expectations were $-1.44. Operator: Good day, and thank you for standing by. Welcome to REGENXBIO’s Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, […]

United statesSteve pakolaHawaiian eyeRetina meetingWorld muscleWestern blotEye careCulturally influential countriesBiotech stocks to buy under